Novartis AG
NVSHealthcare|Drug Manufacturers - General|Switzerland
$152.84
+0.00 (+0.00%)
DCF (FCF)
$89.99
Earnings Power
$56.11
Clinical Trials (530)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06427811 Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | P4 | Active | 85 | Open-label | Asciminib |
| NCT05303285 A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis | Ankylosing Spondylitis (AS) | P4 | Recruiting | 100 | RCT, Double-blind | Secukinumab 300mg s.c., Secukinumab 150mg s.c. |
| NCT06733922 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS | Relapsing Remitting Multiple Sclerosis (RRMS) | P4 | Recruiting | 224 | Open-label | — |
| NCT06498050 Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema | Diabetic Macular Edema | P4 | Active | 52 | Open-label | intravitreal injection of Brolucizumab 6 mg in study eye |
| NCT02344472 Detect V / CHEVENDO (Chemo vs. Endo) | Metastatic Breast Cancer | P3 | Active | 271 | RCT, Open-label | pertuzumab, Trastuzumab, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, nab-Paclitaxel, eribulin, leuprorelin, goserelin |
| NCT04111978 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | P3 | Recruiting | 540 | RCT, Double-blind | Letrozole 2.5mg |
| NCT06496581 Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) | Prostate Cancer Metastatic | P3 | Recruiting | 500 | RCT, Open-label | 177Lu-PMSA-617, Standard of Care |
| NCT04094311 Study of Out of Specification for Tisagenlecleucel | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | P3 | Recruiting | 200 | Open-label | CTL019 |
| NCT00470223 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma | Sarcoma | P3 | Active | 318 | RCT, Open-label | cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid |
| NCT07237256 Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | Breast Cancer | P3 | Recruiting | 3,902 | RCT, Open-label | Chemotherapy followed by endocrine therapy and ribociclib treatment |
| NCT06267560 Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | P3 | Active | 422 | RCT, Double-blind | TQJ230, Placebo |
| NCT02445222 CAR-T Long Term Follow Up (LTFU) Study | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | P3 | Recruiting | 1,400 | Open-label | — |
| NCT06868212 A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | Chronic Spontaneous Urticaria (CSU) | P3 | Recruiting | 400 | RCT, Double-blind | Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection |
| NCT01892722 Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | Multiple Sclerosis | P3 | Active | 240 | RCT, Double-blind | Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection |
| NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | Breast Cancer | P3 | Active | 234 | RCT, Double-blind | Alpelisib, Fulvestrant, Alpelisib-matching placebo |
| NCT02925234 The Drug Rediscovery Protocol (DRUP Trial) | Cancer, Tumors | P2 | Recruiting | 1,550 | Open-label | Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib |
| NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Melanoma | P2 | Active | 134 | RCT, Open-label | LXH254, LTT462, Trametinib, Ribociclib |
| NCT04524000 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | Advanced Breast Cancer | P2 | Active | 24 | Open-label | Alpelisib, Fulvestrant |
| NCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | IgA Nephropathy | P1P2 | Active | 103 | RCT, Double-blind | BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses, BION-1301 Single Dose |
| NCT05518110 PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer | Pancreatic Cancer | P2 | Recruiting | 22 | Open-label | Trametinib, Hydroxychloroquine |
| NCT07203001 A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | Still´s Disease | P2 | Recruiting | 20 | Open-label | MAS825 |
| NCT01990196 Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | Prostate Cancer | P2 | Active | 45 | RCT, Open-label | degarelix, enzalutamide, trametinib, dasatinib |
| NCT02143726 Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | Refractory Hurthle Cell Thyroid Cancer | P2 | Active | 35 | RCT, Open-label | sorafenib, everolimus |
| NCT06910813 DFT383 in Pediatric Participants With Nephropathic Cystinosis | Nephropathic Cystinosis | P1P2 | Recruiting | 30 | Open-label | — |
| NCT05222529 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | Asthma | P2 | Recruiting | 42 | RCT, Double-blind | Glycopyrronium bromide 25ug, Placebo, Glycopyrronium bromide 12.5ug |
| NCT06947993 Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Recruiting | 224 | RCT, Double-blind | GHZ339, Placebo |
| NCT06868290 Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA | ANCA Associated Vasculitis (AAV) | P2 | Recruiting | 126 | RCT, Single-blind | Rapcabtagene autoleucel, Glucocorticoids |
| NCT03906292 Frontline Asciminib Combination in Chronic Phase CML | Chronic Myeloid Leukemia | P2 | Active | 125 | Open-label | Imatinib, Nilotinib 300 mg, Dasatinib, Asciminib |
| NCT05646381 A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Aortic Stenosis | P2 | Recruiting | 502 | RCT, Double-blind | Pelacarsen (TQJ230) 80mg, Matching placebo |
| NCT01273610 Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Breast Neoplasms, HER2/Neu Positive | P2 | Active | 40 | Open-label | Lapatinib, Trastuzumab |
| NCT06430671 Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis (RRMS) | P1 | Active | 11 | Open-label | CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs |
| NCT02393625 Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | ALK-positive NSCLC | P1 | Active | 57 | Open-label | Ceritinib (LDK378), Nivolumab |
| NCT02494882 Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | Acute Lymphoblastic Leukemia | P1 | Active | 12 | Open-label | Ruxolitinib, Dasatinib, Dexamethasone |
| NCT05944562 Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | Mycosis Fungoides, Sezary Syndrome | P1 | Active | 24 | Open-label | Tulmimetostat |
| NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Breast Cancer | P1 | Recruiting | 48 | Open-label | [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant |
| NCT03091257 A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Active | 30 | Open-label | Dabrafenib, Trametinib |
| NCT05017142 Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | Optic Neuritis, Transverse Myelitis | Recruiting | 500 | — | — | |
| NCT03577197 Southeast Netherlands Advanced Metastatic Breast Cancer Registry | Advanced Breast Cancer, Metastatic Breast Cancer | Recruiting | 7,000 | — | — | |
| NCT04671693 A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. | Late Effects, Testicular Germ Cell Tumor Mixed | N/A | Active | 500 | Open-label | — |
| NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic | Recruiting | 12,400 | — | — | |
| NCT04497285 Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer | Metastatic Breast Cancer | Active | 600 | — | — | |
| NCT05009160 DreaMS - Validation Study 1 | Multiple Sclerosis | Active | 300 | — | — | |
| NCT03349801 Development of Novel Clinical Endpoints in Intermediate AMD | Age Related Macular Degeneration (AMD) | Active | 718 | — | — | |
| NCT05918666 National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active | 2,098 | — | — | |
| NCT06785675 Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab. | Hidradenitis Suppurativa | Active | 48 | — | — | |
| NCT06514521 Post Marketing Study on Pluvicto in Korea | Metastatic Castration-resistant Prostate Cancer | Recruiting | 278 | — | — | |
| NCT06931691 A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 80 | — | LNP023 | |
| NCT05703516 A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea | Non-Small-Cell Lung Carcinoma | Recruiting | 250 | — | — | |
| NCT03292094 The African-PREDICT Study | Cardiovascular Diseases, Hypertension | Active | 1,202 | — | — | |
| NCT06770543 Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) | Primary Hypercholesterolemia or Mixed Dyslipidemia | Recruiting | 1,500 | — | — | |
| NCT05399992 Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | Primary Hypercholesterolemia, Mixed Dyslipidemia | Active | 847 | — | — | |
| NCT07465679 A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan | Heart Failure With Reduced Ejection Fraction | Active | 500 | — | — | |
| NCT06053749 An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden | Multiple Sclerosis (MS) | Active | 4 | — | Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs) | |
| NCT06517719 Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer | Metastatic Castration Resistant Prostate Cancer | Recruiting | 500 | — | — | |
| NCT01266837 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) | Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy | P4 | Completed | 64 | Open-label | Everolimus |
| NCT01521715 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell | P4 | Completed | 44 | Open-label | Pazopanib |
| NCT02248571 Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast | P4 | Completed | 85 | RCT, Open-label | Bevacizumab, Capecitabine, Everolimus, Exemestane |
| NCT07488520 Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire | Sickle Cell Disease (SCD) | P4 | Not Yet Recruiting | 120 | Open-label | — |
| NCT00564941 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload | Myelodysplastic Syndromes, Beta-Thalassemia | P4 | Completed | 309 | Open-label | deferasirox |
| NCT01239472 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant | Renal Transplant Rejection, Immunosuppression | P4 | Completed | 30 | RCT, Open-label | Everolimus |
| NCT00154271 Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) | Hypertension | P4 | Completed | 1,677 | RCT, Open-label | Valsartan, Valsartan HCT |
| NCT00477334 Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients | Genital Herpes | P4 | Completed | 463 | RCT, Double-blind | Famciclovir, Placebo |
| NCT00138528 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome | Metabolic Syndrome | P4 | Completed | 55 | RCT, Double-blind | Fluvastatin |
| NCT01551212 Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients | Liver Transplantation | P4 | Completed | 339 | RCT, Open-label | Everolimus, Tacrolimus, Corticosteroids |
| NCT00139555 Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension | Hypertension, Left Ventricular Hypertrophy | P4 | Completed | 125 | RCT, Double-blind | amlodipine/benazepril |
| NCT00219271 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer | Prostate Cancer | P4 | Completed | 60 | Open-label | Zoledronic acid |
| NCT03977649 A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients | Migraine Disorders | P4 | Completed | 62 | RCT, Double-blind | erenumab, placebo |
| NCT01349114 Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects | Diabetes, Pre-hypertension | P4 | Terminated | 21 | RCT, Double-blind | aliskiren 300 mg once daily, Placebo/sugar pill |
| NCT00367393 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis | Atopic Dermatitis | P4 | Completed | 41 | Open-label | Pimecrolimus cream 1% |
| NCT00980018 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment | Chronic Myelogenous Leukemia | P4 | Completed | 52 | Open-label | Nilotinib |
| NCT00787917 An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) | Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis | P4 | Terminated | 14 | RCT, Double-blind | Omalizumab, Placebo, Itraconazole |
| NCT04297618 The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers | Dry Eye | P4 | Completed | 45 | Open-label | Xiidra |
| NCT00931710 Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension | Stage 2 Systolic Hypertension | P4 | Completed | 488 | RCT, Double-blind | valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ |
| NCT02752776 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. | Plaque Psoriasis | P4 | Completed | 1,660 | Open-label | Secukinumab |
| NCT02634983 QVA Mechanistic Efficacy Study (Receptor Effects, Etc) | Chronic Obstructive Pulmonary Disease | P4 | Completed | 31 | RCT, Double-blind | QVA149, Placebo |
| NCT00171977 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) | Gastrointestinal Stromal Tumors | P4 | Completed | 64 | Open-label | Imatinib Mesylate |
| NCT00853957 Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension | Hypertension | P4 | Completed | 443 | RCT, Double-blind | Aliskiren/Amlodipine, Amlodipine |
| NCT00219219 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases | Prostate Cancer | P4 | Completed | — | Open-label | Zoledronic acid |
| NCT00241085 Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus | PROTEINURIA, Hypertension | P4 | Completed | 392 | RCT, Double-blind | valsartan |
| NCT00529269 Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms | Renal Transplant | P4 | Completed | 200 | Single-blind | Enteric-Coated Mycophenolate Sodium (EC-MPS) |
| NCT00171509 Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients | Liver Transplant | P4 | Completed | 61 | RCT, Open-label | Cyclosporine microemulsion |
| NCT01546415 Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia | Iron Overload | P4 | Completed | 64 | Open-label | Desferasirox |
| NCT01543828 Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | COPD | P4 | Completed | 40 | RCT, Double-blind | indacaterol, placebo |
| NCT02178540 Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients | Cystic Fibrosis | P4 | Completed | 45 | Open-label | Placebo |
| NCT00312143 Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients | De Novo Kidney Transplant Recipients | P4 | Completed | 35 | Open-label | Enteric-coated Mycophenolate sodium (EC-MPS) |
| NCT00260208 Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus | Liver Transplant, Hepatitis C | P4 | Terminated | 361 | RCT, Open-label | Cyclosporine A, Tacrolimus |
| NCT00237159 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis | Prostate Cancer Patients With Bone Metastasis | P4 | Completed | 284 | Open-label | Zoledronic acid |
| NCT02248922 Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa | Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis | P4 | Terminated | 17 | Open-label | TIS or TIP |
| NCT00414765 Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | Metastatic Renal Cell Carcinoma, Metastatic Melanoma | P4 | Completed | 26 | Open-label | Aldesleukin |
| NCT02145611 Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension | Type 2 Diabetes Mellitus, Hypertension | P4 | Completed | 50 | RCT, Open-label | Glibenclamide, Vildagliptin |
| NCT00296244 Steroid Free Immunosuppression in Liver Transplantation | Liver Cirrhosis, Liver Transplant Disorder | P4 | Completed | 40 | RCT, Open-label | Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA) |
| NCT00622713 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) | Alzheimer's Disease | P4 | Completed | 228 | Open-label | Rivastigmine transdermal patch |
| NCT04679935 Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration | Age-related Macular Degeneration | P4 | Completed | 52 | RCT, Open-label | Brolucizumab |
| NCT00666536 The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy | Hypertension | P4 | Completed | 728 | RCT, Double-blind | valsartan and amlodipine, valsartan and amlodipine |
| NCT01922271 Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P4 | Completed | 152 | RCT, Double-blind | NVA237, Tiotropium, Placebo to NVA237, Placebo to tiotropium, Salbutamol |
| NCT00219310 RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir | Recurrent Genital Herpes (RGH) | P4 | Completed | — | RCT, Open-label | Famciclovir |
| NCT00654589 Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload | Iron Overload | P4 | Completed | 75 | Open-label | Deferasirox |
| NCT01988662 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) | Neovacular Age-related Macular Degeneration | P4 | Completed | 205 | RCT, Double-blind | — |
| NCT00160966 Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy | Polyomavirus Infections | P4 | Completed | 108 | RCT, Open-label | Ciclosporin and Mycophenolate-mofetil, Tacrolimus and Mycophenolate-mofetil, Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus |
| NCT00171275 Fluvastatin in the Therapy of Acute Coronary Syndrome | Coronary Disease, Myocardial Infarction | P4 | Completed | 1,000 | RCT, Double-blind | Fluvastatin |
| NCT04464694 Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema | Proliferative Diabetic Retinopathy, Diabetic Macular Edema | P4 | Unknown | 142 | RCT, Single-blind | Ranibizumab |
| NCT01845025 Study of Safety of Foradil in Patients With Persistent Asthma | Persistent Asthma | P4 | Terminated | 827 | RCT, Double-blind | Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo |
| NCT00170898 Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain | Musculoskeletal Pain | P4 | Completed | 419 | RCT, Double-blind | Lumiracoxib |
| NCT00376064 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly | Acromegaly | P4 | Completed | 20 | Open-label | Octreotide acetate and cabergoline/Octrotide and Somavert |
| NCT00400647 Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil | Maintenance Kidney Transplant | P4 | Completed | 136 | RCT, Open-label | Enteric-coated Mycophenolate sodium (EC-MPS), Mycophenolate mofetil |
| NCT04491136 Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM) | Heart Failure | P4 | Terminated | 201 | Open-label | ACEI/ARB, ARNI |
| NCT01686932 Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function | Diabetes Mellitus Type 2 | P4 | Completed | 51 | RCT, Open-label | Vildagliptin, Sitagliptin |
| NCT00248144 A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis | Recurrent Herpes Labialis | P4 | Completed | — | RCT, Double-blind | Famciclovir |
| NCT00674323 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy | Polypoidal Choroidal Vasculopathy | P4 | Completed | 61 | RCT, Double-blind | Verteporfin Photodynamic Therapy, Ranibizumab |
| NCT00154297 Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients | Renal Transplantation | P4 | Completed | 139 | RCT, Open-label | Everolimus (RAD001) |
| NCT00489424 Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass | Osteoporosis | P4 | Completed | 793 | RCT, Double-blind | Placebo, Acetaminophen, Fluvastatin |
| NCT00237224 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole | Breast Cancer | P4 | Completed | 40 | Open-label | Letrozole |
| NCT00835159 Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial | Delirium, Postoperative Cognitive Dysfunction | P4 | Completed | 30 | RCT, Double-blind | Rivastigmine Patch |
| NCT00386750 Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function | Malaria, Falciparum | P4 | Terminated | 265 | RCT, Open-label | Artemether-lumefantrine |
| NCT00139594 Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder | Bipolar Disorder | P4 | Completed | 181 | Open-label | licarbazepine |
| NCT04662931 An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients | Sickle Cell Disease (SCD) | P4 | Completed | 140 | Open-label | crizanlizumab |
| NCT00760266 Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population | Hypertension | P4 | Completed | 451 | RCT, Double-blind | Aliskiren, Hydrochlorothiazide |
| NCT00150085 Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion | Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients | P4 | Terminated | 50 | RCT, Open-label | cyclosporine micro-emulsion |
| NCT01153425 µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis | Osteoporosis, Osteopenia | P4 | Completed | 33 | RCT, Open-label | Teriparatide, Zoledronic Acid |
| NCT00565474 Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant | Graft Vasculopathy | P4 | Completed | 84 | RCT, Double-blind | Fluvastatin |
| NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients | Rheumatoid Arthritis, Psoriatic Arthritis | P4 | Completed | 841 | RCT, Open-label | Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab |
| NCT00304226 Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy | Hypertension | P4 | Completed | 1,288 | RCT, Double-blind | valsartan, amlodipine |
| NCT01129557 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease, Diabetic Nephropathy | P4 | Terminated | 46 | RCT, Open-label | Aliskiren, Valsartan |
| NCT02523287 Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses | Safety Markers of Adjuvanted Influenza Vaccine | P4 | Completed | 240 | RCT, Double-blind | Fluad, Saline |
| NCT00171847 Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer | Metastatic Breast Cancer | P4 | Terminated | 93 | RCT, Open-label | Letrozole, Trastuzumab plus Letrozole, Letrozole |
| NCT01043874 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response | Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase | P4 | Completed | 45 | Open-label | Nilotinib |
| NCT02080559 Investigating the Immune Response to 4CMenB in Infants | Meningitis | P4 | Completed | 187 | RCT, Open-label | 4CMenB |
| NCT00170859 Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients | Heart Transplantation | P4 | Completed | — | RCT, Open-label | Everolimus |
| NCT04667949 Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients | Relapsing Multiple Sclerosis (RMS) | P4 | Completed | 98 | Open-label | Fingolimod 0.5mg |
| NCT01019980 Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections | Fever | P4 | Terminated | 2 | RCT, Double-blind | Diclofenac potassium, Acetaminophen |
| NCT00128297 Pamidronate Administration in Breast Cancer Patients With Bone Metastases | Breast Cancer, Neoplasm Metastasis | P4 | Completed | 152 | RCT, Open-label | Pamidronate |
| NCT01028092 mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation | Renal Transplant | P3 | Completed | 327 | RCT, Open-label | Anti R-IL2 + Cyclosporine, Thymoglobulin + Everolimus, Anti R-IL2 + Cyclosporine then Everolimus |
| NCT04828161 A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 | COVID-19 | P2P3 | Terminated | 407 | RCT, Double-blind | ensovibep, Placebo |
| NCT01803763 Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients | Chronic Urticaria, Chronic Idiopathic Urticaria | P2P3 | Completed | 30 | RCT, Double-blind | Omalizumab (Xolair), Placebo |
| NCT00219739 STI571 ProspectIve RandomIzed Trial: SPIRIT | Chronic Myeloid Leukemia | P3 | Completed | 789 | RCT, Open-label | Imatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon, Imatinib mesylate 400 mg + Cytarabine |
| NCT03462251 Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line | Breast Cancer, Hormone Receptor Positive Tumor | P3 | Completed | 41 | RCT, Open-label | — |
| NCT00433589 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | Breast Cancer | P3 | Completed | 6,600 | RCT, Open-label | anthracycline-based, docetaxel and capecitabine, tamoxifen, Letrozole |
| NCT01226953 Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants | Haemophilus Influenzae Type b (Hib) Infection | P3 | Completed | 660 | RCT, Single-blind | Haemophilus influenzae type b (Hib) vaccine |
| NCT03681093 Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma | Nasal Polyps | P3 | Completed | 98 | RCT, Double-blind | Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo |
| NCT04816214 Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy | Carcinoma, Non-Small-Cell Lung | P3 | Terminated | 6 | RCT, Open-label | Capmatinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin |
| NCT00504244 Myfortic Versus Azathioprine in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P3 | Terminated | 12 | RCT, Open-label | switch to Myfortic, continuation of azathioprine |
| NCT00311415 Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children | Prevention of Meningococcal Infection | P3 | Completed | 257 | RCT, Open-label | Meningococcal C conjugate vaccine |
| NCT01478347 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults | Meningococcal Disease, Meningococcal Meningitis | P3 | Completed | 18 | Open-label | Recombinant meningococcal B + OMV NZ |
| NCT00260923 A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure | Hypertension | P3 | Completed | 641 | RCT, Double-blind | aliskiren |
| NCT01410448 Everolimus in de Novo Kidney Transplant Recipients | Kidney Transplantation | P3 | Completed | 383 | RCT, Open-label | Everolimus, Mycophenolate sodium, Cyclosporine, Steroids |
| NCT00232115 Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis | Perioral Dermatitis | P3 | Completed | 124 | RCT, Double-blind | Pimecrolimus, Placebo |
| NCT03461289 Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 | SMA | P3 | Completed | 33 | Open-label | Onasemnogene Abeparvovec-xioi |
| NCT01365455 Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year | Moderate to Severe Plaque-type Psoriasis | P3 | Completed | 738 | RCT, Double-blind | secukinumab 150 mg, placebo to secukinumab 150 mg |
| NCT00785785 A Study of Nilotinib Versus Imatinib in GIST Patients | Gastrointestinal Stromal Tumor (GIST) | P3 | Completed | 644 | RCT, Open-label | Nilotinib (AMN107), imatinib (STI571) |
| NCT00057265 A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B | Chronic Hepatitis B | P3 | Completed | — | RCT, Double-blind | telbivudine or lamivudine |
| NCT01155700 Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) | Allergic Asthma | P3 | Completed | 51 | Open-label | omalizumab |
| NCT02409667 Plaque Psoriasis Efficacy and Safety With Secukinumab | Plaque Psoriasis | P3 | Completed | 16,487 | RCT, Double-blind | Secukinumab |
| NCT01377012 Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents | Rheumatoid Arthritis | P3 | Completed | 637 | RCT, Double-blind | Secukinumab (AIN457), Placebo |
| NCT00402428 Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients | Chronic Hepatitis C | P3 | Completed | 1,331 | RCT, Open-label | albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin |
| NCT05232864 Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis | Lupus Nephritis | P3 | Terminated | 31 | Open-label | Secukinumab |
| NCT00351832 A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 236 | RCT, Double-blind | Vildagliptin |
| NCT00180011 Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma | Asthma | P2P3 | Completed | 18 | Double-blind | Omalizumab |
| NCT01396057 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) | Visual Impairment, Macular Edema | P3 | Completed | 244 | RCT, Double-blind | Ranibizumab |
| NCT00073528 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | Breast Neoplasms | P3 | Completed | 1,286 | RCT, Double-blind | Lapatinib, Letrozole, Placebo |
| NCT01012765 Effect of Indacaterol on Inspiratory Capacity (IC) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 173 | RCT, Double-blind | Indacaterol, Tiotropium, Placebo |
| NCT00130351 A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma | Asthma | P3 | Completed | 155 | Open-label | — |
| NCT00894387 Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure | Acute Decompensated Heart Failure, Congestive Heart Failure | P3 | Completed | 1,639 | RCT, Double-blind | Aliskiren, Placebo |
| NCT00383435 Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 1,055 | RCT, Double-blind | Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI, Placebo |
| NCT00392262 A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients | Hypertension | P3 | Completed | 224 | RCT, Open-label | valsartan + amlodipine |
| NCT01599650 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion | Branch Retinal Vein Occlusion | P3 | Completed | 455 | RCT, Open-label | Ranibizumab |
| NCT02107807 Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine | Influenza, Human, Flu, Human | P3 | Completed | 539 | RCT, Double-blind | Novartis Investigational H5N1 vaccine, Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine, Novartis Seasonal Influenza Vaccine |
| NCT01099436 Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients | Breast Cancer | P3 | Completed | 250 | RCT, Open-label | cyclophosphamide, docetaxel, doxorubicin hydrochloride, zoledronic acid |
| NCT00099944 Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 515 | RCT, Double-blind | vildagliptin, Glimepiride, LAF237 placebo |
| NCT01857206 Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age | Influenza, Fever | P3 | Completed | 2,055 | RCT, Single-blind | Mammalian cell based flu vaccine, Egg based flu vaccine |
| NCT01327664 Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis | Uveitis | P3 | Withdrawn | — | Open-label | AIN457 |
| NCT04597632 An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study | Neovascular Age-related Macular Degeneration | P3 | Completed | 248 | Open-label | brolucizumab |
| NCT02471144 Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis | Chronic Severe Plaque-type Psoriasis | P3 | Completed | 162 | RCT, Double-blind | Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept |
| NCT01948830 Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD | Age-related Macular Degeneration, Choroidal Neovascularization | P3 | Completed | 650 | RCT, Single-blind | Ranibizumab 0.5mg, Ranibizumab 0.5mg |
| NCT00925873 GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | Acute Myeloid Leukemia | P3 | Completed | 303 | RCT, Open-label | Active comparator (no fludarabine), Experimental (fludarabine) |
| NCT00770081 Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) | Diabetes Mellitus, Type 2, Renal Insufficiency | P3 | Completed | 75 | RCT, Double-blind | vildagliptin, sitagliptin |
| NCT02721966 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement | Axial Psoratic Arthritis | P3 | Completed | 503 | RCT, Double-blind | Secukinumab, Secukinumab and Placebo |
| NCT05386680 Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam | Spinal Muscular Atrophy | P3 | Completed | 27 | Open-label | — |
| NCT00865280 Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) | Skin Diseases, Infectious | P3 | Terminated | 143 | RCT, Double-blind | PTK 0796, linezolid, moxifloxacin |
| NCT01497262 Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | P3 | Completed | 162 | Open-label | Fingolimod |
| NCT00508274 Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | Neoplasms, Breast | P3 | Terminated | 52 | Open-label | lapatinib, capecitabine |
| NCT00171041 A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age | Hypertension | P3 | Completed | 265 | RCT, Double-blind | valsartan |
| NCT01640951 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis | Moderate to Severe Chronic Plaque-Type Psoriasis | P3 | Completed | 675 | Double-blind | AIN457 150 mg, AIN457 300 mg, Placebo |
| NCT01030770 Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: | Diabetes Complications | P2P3 | Completed | 25 | RCT, Double-blind | Ranibizumab, 0.9% Sodium Chloride |
| NCT00624286 Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 416 | RCT, Double-blind | Indacaterol 150 μg, Placebo to indacaterol |
| NCT00396656 Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients | Hypertension | P3 | Completed | 30 | RCT, Open-label | Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan |
| NCT02595970 Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis | Psoriasis | P3 | Completed | 120 | Open-label | Secukinumab |
| NCT00058188 Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation | Osteoporosis, Prostate Cancer | P3 | Terminated | 53 | RCT, Open-label | calcium gluconate, zoledronic acid |
| NCT01294787 Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) | COPD | P3 | Completed | 85 | RCT, Double-blind | indacaterol and glycopyrronium bromide (QVA149), placebo, tiotropium |
| NCT01998477 A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications | Influenza | P3 | Completed | 430 | RCT, Double-blind | TIVc, TIV |
| NCT01259492 Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD) | Attention Deficit/Hyperactivity Disorder | P3 | Completed | 725 | RCT, Double-blind | Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg |
| NCT00138567 Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 530 | RCT, Double-blind | vildagliptin |
| NCT00464672 Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old | Influenza | P3 | Completed | 1,893 | RCT, Double-blind | Influenza virus vaccine, Comparator influenza vaccine |
| NCT00411099 Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 508 | RCT, Double-blind | agomelatine, placebo |
| NCT01392495 Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P3 | Terminated | 17 | Open-label | Imatinib |
| NCT00254475 A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia | Essential Hypertension, Hypercholesterolemia | P3 | Completed | 871 | RCT, Double-blind | simvastatin, valsartan |
| NCT00050934 Pediatric Epilepsy Study | Epilepsy, Epilepsies, Partial | P3 | Completed | 132 | — | oxcarbazepine |
| NCT01007149 Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma | Asthma | P3 | Completed | 79 | RCT, Double-blind | omalizumab, Placebo |
| NCT00351585 A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 39 | RCT, Double-blind | Vildagliptin |
| NCT04838626 Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection | Prostatic Neoplasms, Prostate Cancer | P2P3 | Completed | 195 | Open-label | [18F]CTT1057 |
| NCT01000311 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months | Meningococcal Disease | P3 | Completed | 529 | RCT, Open-label | MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR |
| NCT00355134 Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | P3 | Completed | 1,083 | RCT, Double-blind | Fingolimod, Placebo |
| NCT03096834 A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies | Episodic Migraine | P3 | Completed | 246 | RCT, Double-blind | AMG334 (70 mg) Pre-Filled Syringe (PFS), Placebo Pre-Filled Syringe (PFS) |
| NCT01709903 A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 | Chronic Obstructive Pulmonary Disease | P3 | Completed | 744 | RCT, Double-blind | QVA149, Fluticasone/salmeterol, Placebo to QVA149, Placebo to fluticasone/salmeterol |
| NCT00150046 Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients | Heart Transplantation | P3 | Completed | 176 | RCT, Open-label | Everolimus |
| NCT01470989 β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) | Acute Gouty Arthritis Flares | P3 | Completed | 136 | Open-label | ACZ885, Triamcinolone acetonide 40 mg |
| NCT00219323 Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma. | Asthma | P3 | Completed | 133 | Open-label | Omalizumab |
| NCT00382096 Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 1,179 | RCT, Double-blind | Vildagliptin, Metformin, Vildagliptin + Metformin |
| NCT01095250 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis | Uveitis | P3 | Terminated | 30 | RCT, Double-blind | AIN457, AIN457, AIN457, Placebo |
| NCT00622635 A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 68 | RCT, Double-blind | Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg |
| NCT01023308 Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | Multiple Myeloma | P3 | Completed | 767 | RCT, Double-blind | Panobinostat, Bortezomib, Dexamethasone, Placebo |
| NCT00329940 Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | Breast Cancer | P3 | Completed | 200 | Open-label | Letrozole |
| NCT02571777 Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma | Asthma | P3 | Completed | 3,092 | RCT, Double-blind | QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320, QMF149 150/160, salmeterol/fluticasone |
| NCT00099229 Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder | Bipolar Disorder | P3 | Completed | 320 | RCT, Double-blind | Licarbazepine |
| NCT00908531 Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer | Operable Breast Neoplasms | P3 | Terminated | 123 | RCT, Open-label | letrozole (Femara) |
| NCT05795153 A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. | Chronic Spontaneous Urticaria | P3 | Completed | 144 | Open-label | LOU064 |
| NCT02032173 Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase | Macular Edema, Macular Degeneration | P3 | Terminated | 31 | Open-label | Ranibizumab 0.5mg |
| NCT00886769 Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) | Systemic Juvenile Idiopathic Arthritis | P3 | Terminated | 84 | RCT, Double-blind | Canakinumab, Placebo |
| NCT00909961 A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years | Postmenopausal Osteoporosis | P3 | Completed | 118 | Open-label | Zoledronic acid |
| NCT00514514 Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen | Kidney Transplantation | P3 | Completed | 802 | RCT, Open-label | Everolimus, Myfortic, Sandimmun Optoral, Simulect® |
| NCT00050947 Pediatric Epilepsy Study | Epilepsy | P3 | Completed | 94 | — | oxcarbazepine |
| NCT00645411 Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents | Influenza | P2P3 | Completed | 3,604 | RCT, Single-blind | Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV), Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV) |
| NCT03066609 Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis | Plaque Psoriasis | P3 | Completed | 543 | RCT, Double-blind | Secukinumab 150 mg s.c., Secukinumab 300 mg s.c., Placebo |
| NCT01663233 Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine | Essential Hypertension | P3 | Completed | 266 | RCT, Double-blind | LCZ696, Amlodipine, Placebo |
| NCT00731692 This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. | Primary Progressive Multiple Sclerosis | P3 | Terminated | 970 | RCT, Double-blind | FTY720, Placebo |
| NCT01243944 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | Polycythemia Vera | P3 | Completed | 222 | RCT, Open-label | ruxolitinib tablets |
| NCT02042014 Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan | Severe Pulmonary Arterial Hypertension | P3 | Completed | 8 | Open-label | QTI571 |
| NCT02226120 Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction | Chronic Heart Failure With Reduced Ejection Fraction | P3 | Completed | 1,980 | Open-label | LCZ696 |
| NCT03386474 Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD | Neovascular Age-related Macular Degeneration | P3 | Completed | 151 | Double-blind | Brolucizumab 6 mg, Aflibercept 2 mg |
| NCT00241020 Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | P3 | Completed | 270 | Double-blind | Octreotide |
| NCT02474082 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. | Psoriasis | P3 | Completed | 202 | RCT, Single-blind | Secukinumab, Fumaric acid |
| NCT04717635 Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD | Adult Onset Still's Disease | P3 | Completed | 14 | Open-label | Canakinumab |
| NCT03810313 Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion | Central Retinal Vein Occlusion | P3 | Terminated | 493 | RCT, Double-blind | Brolucizumab 6 mg, Aflibercept 2 mg |
| NCT00215943 Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | Multiple Myeloma | P3 | Terminated | 90 | RCT, Open-label | zoledronic acid, dexamethasone, thalidomide, vincristine, adriamycin |
| NCT00138515 Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 418 | RCT, Double-blind | vildagliptin |
| NCT05776927 A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. | Asthma | P3 | Not Yet Recruiting | 304 | RCT, Double-blind | QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication |
| NCT01199861 Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) | Relapsing Multiple Sclerosis | P3 | Completed | 138 | RCT, Double-blind | Fingolimod, Placebo, Seasonal influenza vaccine, Tetanus toxoid vaccine |
| NCT01105507 The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada | Cryopyrin Associated Periodic Syndrome | P3 | Completed | 4 | Open-label | canakinumab (company code: ACZ885D) |
| NCT00510068 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors | Advanced Neuroendocrine Tumors of Pancreatic Origin | P3 | Completed | 410 | RCT, Double-blind | Everolimus, Everolimus Placebo |
| NCT04300309 Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria | Plasmodium Falciparum Malaria | P2P3 | Terminated | 28 | Open-label | artemether:lumefantrine (2.5 mg:30 mg) |
| NCT01811485 Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy | Diabetes Mellitus, Type 2 | P3 | Completed | 171 | RCT, Double-blind | LMF237 50/250 mg, LMF237 50/500 mg, Placebo |
| NCT01200589 Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy | Non-Hodgkin's Lymphoma | P3 | Terminated | 438 | RCT, Open-label | Ofatumumab, Rituximab, Ofatumumab, Rituximab |
| NCT02437318 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | Breast Cancer | P3 | Completed | 572 | RCT, Double-blind | Fulvestrant, Alpelisib, Placebo |
| NCT02720536 Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation | Chronic Iron Overload | P3 | Completed | 53 | Open-label | Deferasirox |
| NCT00171457 The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia. | Heartburn, Dyspepsia | P3 | Completed | 24 | RCT, Double-blind | Tegaserod |
| NCT03867201 Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients | Migraine | P3 | Completed | 557 | RCT, Double-blind | Erenumab |
| NCT00242567 Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer | Prostate Cancer | P3 | Completed | 522 | RCT, Open-label | Zoledronic Acid, Androgen Deprivation Therapy (ADT) |
| NCT04005352 Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) | Age-related Macular Degeneration | P3 | Completed | 734 | RCT, Double-blind | Brolucizumab 6 mg, Aflibercept 2 mg |
| NCT00084071 Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia | Pneumonia | P3 | Completed | 2,136 | RCT, Double-blind | Tifacogin |
| NCT01827930 Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response | Leukemia, Myeloid, Chronic-Phase | P3 | Terminated | 68 | RCT, Open-label | Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate |
| NCT00399659 Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. | Opioid-induced Constipation | P3 | Terminated | 360 | Open-label | Tegaserod |
| NCT01232478 I Change Adherence & Raise Expectations | Cystic Fibrosis | P3 | Completed | 641 | RCT, Open-label | — |
| NCT00413049 Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension | Hypertension | P3 | Completed | 698 | RCT, Double-blind | Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg |
| NCT00049959 Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. | Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome | P3 | Terminated | — | RCT, Single-blind | verteporfin PDT |
| NCT00046748 Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma | Asthma | P3 | Completed | 484 | RCT, Double-blind | Omalizumab |
| NCT01773460 Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane | Metastatic Breast Cancer | P3 | Terminated | 3 | RCT, Double-blind | Everolimus, Everolimus-placebo |
| NCT00701259 Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn | Frequent Heartburn | P3 | Completed | 852 | RCT, Double-blind | Lansoprazole, Lansoprazole, placebo |
| NCT00567697 A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO | Central Retinal Vein Occlusion, Macular Edema | P3 | Completed | 32 | RCT, Double-blind | ranibizumab, ranibizumab |
| NCT01137682 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly | Acromegaly | P3 | Completed | 198 | RCT, Double-blind | Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg |
| NCT01393340 Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma | Nasal Polyposis, Asthma | P2 | Completed | 23 | RCT, Double-blind | Omalizumab, Placebo |
| NCT00719264 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | Carcinoma, Adenocarcinoma | P2 | Completed | 365 | RCT, Open-label | RAD001(everolimus), interferon alfa-2a, bevacizumab |
| NCT02404844 Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | Breast Cancer | P2 | Completed | 48 | Open-label | BKM120, Tamoxifen |
| NCT01520103 Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer | Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer | P2 | Completed | 139 | RCT, Open-label | Vinorebine, Everolimus, Vinorelbine |
| NCT00784446 First-line Therapy of Stage IV Colorectal Cancer | Stage IV Colorectal Cancer | P1P2 | Completed | 51 | Open-label | Oxaliplatin, Capecitabine, Bevacizumab, Imatinib |
| NCT00413829 Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) | Age Related Macular Degeneration | P2 | Completed | 20 | Open-label | Intravitreal ranibizumab with photodynamic therapy |
| NCT03927690 Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema | Diabetic Macular Edema | P2 | Completed | 91 | RCT, Double-blind | LKA651, Lucentis |
| NCT01123954 Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers | Seasonal Influenza | P2 | Completed | 33 | Open-label | Seasonal flu vaccine |
| NCT03398434 Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation | Atrial Fibrillation | P2 | Withdrawn | — | RCT, Single-blind | MAA868, Apixaban |
| NCT02939599 Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients | Pulmonary Arterial Hypertension | P2 | Terminated | 5 | Open-label | QCC374 |
| NCT02002702 Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients | Acute Heart Failure | P2 | Completed | 46 | RCT, Double-blind | Serelaxin, Placebo |
| NCT01092065 Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia | Parkinson's Disease | P2 | Completed | 23 | RCT, Double-blind | AFQ056 with L-dopa, Placebo |
| NCT01982292 Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure | Chronic Heart Failure | P2 | Completed | 321 | RCT, Double-blind | RLX030 (serelaxin), Placebo |
| NCT04812548 A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants | Myelodysplastic Syndrome (MDS) | P2 | Terminated | 20 | Open-label | sabatolimab, azacitidine, venetoclax |
| NCT01532700 An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia (CLL) | P2 | Completed | 28 | Open-label | Ofatumumab with GSK2110183 |
| NCT01856101 Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy | Carcinoma Transitional Cell | P2 | Terminated | 22 | Open-label | BEZ235 |
| NCT00501852 Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium | Chronic Obstructive Pulmonary Disease | P2 | Completed | 83 | RCT, Double-blind | NVA237, Placebo, Tiotropium |
| NCT00817414 A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension | Hypertension | P2 | Completed | 63 | RCT, Double-blind | LCI699-matching placebo, LCI699 |
| NCT01917318 Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD) | Post Traumatic Stress Disorder | P2 | Terminated | 1 | RCT, Double-blind | Iloperidone, Placebo |
| NCT01353508 Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers | Hypertension | P2 | Completed | 32 | RCT, Double-blind | LCZ696, Valsartan |
| NCT01922089 Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients | Heart Failure With Reduced Ejection Fraction | P2 | Completed | 498 | RCT, Double-blind | LCZ696 |
| NCT00342940 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older | Influenza | P2 | Withdrawn | — | Open-label | influenza surface antigen inactivated vaccine |
| NCT00325325 Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus | Kidney Diseases | P2 | Unknown | 40 | RCT, Open-label | everolimus and tacrolimus |
| NCT01148810 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis | Polymyositis, Dermatomyositis | P2 | Terminated | 18 | RCT, Double-blind | BAF312, Placebo |
| NCT00464880 Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy | Diabetes Type 2 | P1P2 | Completed | 24 | RCT, Double-blind | Aliskiren |
| NCT01784068 Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients | Chronic Myelogenous Leukemia | P2 | Completed | 215 | Open-label | Nilotinib followed by treatment-free |
| NCT00620815 Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above | Influenza | P2 | Completed | 601 | RCT, Single-blind | MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine, Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1, Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine, MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine |
| NCT02696967 A Study of CLR325 in Chronic Stable Heart Failure Patients. | Chronic Stable Heart Failure | P2 | Completed | 26 | RCT, Double-blind | CLR325 |
| NCT01744665 A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation | CML | P2 | Completed | 59 | Open-label | nilotinib |
| NCT00088231 PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | Acute Myelogenous Leukemia, Agnogenic Myeloid Metaplasia | P1P2 | Completed | 9 | Open-label | Imatinib Mesylate (Gleevec), PTK 787 (vatalanib) |
| NCT00233454 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell | P2 | Completed | 26 | Open-label | Midostaurin |
| NCT02515331 Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients | Patients, Resistant Hypertension | P2 | Completed | 64 | RCT, Double-blind | LHW090, Placebo |
| NCT02962895 Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) | Primary Sjogren Syndrome | P2 | Completed | 190 | RCT, Double-blind | VAY736 |
| NCT01402401 Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | Advanced Gastric Cancer | P2 | Terminated | 21 | Open-label | AUY922, Trastuzumab |
| NCT01179737 Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P2 | Terminated | 23 | RCT, Double-blind | Nilotinib, Placebo to nilotinib |
| NCT02414139 Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 373 | Open-label | Capmatinib |
| NCT02132130 Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss | Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss | P1P2 | Completed | 22 | Open-label | CGF166 |
| NCT00633295 Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor | Gastrointestinal Stromal Tumors (GIST) | P2 | Completed | 9 | Open-label | AMN107- NILOTINIB |
| NCT02083354 Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | Cancer, Melanoma | P2 | Completed | 77 | Open-label | Dabrafenib, Trametinib |
| NCT00940602 Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study | Myelodysplastic Syndromes | P2 | Completed | 225 | RCT, Double-blind | Deferasirox, Placebo |
| NCT01406977 Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) | Hypophosphatasia | P2 | Completed | 8 | Open-label | BPS804 |
| NCT01868477 Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. | Low and Int 1-risk Myelodysplastic Syndrome | P2 | Completed | 28 | RCT, Open-label | Deferasirox DFX, DT, Erythropoietin alpha, Deferasirox DFX, FCT |
| NCT00914771 Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects | Pandemic H5N1 Influenza | P2 | Completed | 722 | RCT, Double-blind | H5N1 pandemic Influenza vaccine 3.75µg, H5N1 pandemic Influenza vaccine 7.5µg |
| NCT04365153 Canakinumab in Covid-19 Cardiac Injury (The Three C Study) | COVID-19, SARS-CoV 2 | P2 | Completed | 45 | RCT, Double-blind | Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos |
| NCT00522067 Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases. | Influenza Disease | P2 | Completed | 52 | Open-label | Adjuvanted influenza vaccine |
| NCT00960739 Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma | Neuroblastoma | P2 | Completed | 30 | Open-label | Topotecan hydrochloride |
| NCT00237211 Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | Postmenopausal Women With Advanced Breast Cancer | P2 | Completed | 31 | Open-label | Letrozole |
| NCT01640964 An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension | Compensated Cirrhosis and Portal Hypertension | P2 | Completed | 47 | RCT, Open-label | Terlipressin acetate, Serelaxin (RLX030) |
| NCT02712983 Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection | Non-cystic Fibrosis Bronchiectasis | P2 | Completed | 107 | RCT, Double-blind | TIP, TIP and placebo, Placebo |
| NCT03610724 Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients | Non-Hodgkin Lymphoma | P2 | Completed | 34 | Open-label | Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy |
| NCT01874340 Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | P2 | Terminated | 28 | RCT, Double-blind | Placebo, AIN457 |
| NCT02649218 A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients | Chronic Spontaneous Urticaria | P2 | Completed | 226 | Open-label | Ligelizumab |
| NCT01018732 A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY | Meningococcal Disease, Meningococcal Meningitis | P2 | Completed | 155 | Open-label | Novartis Meningococcal (MenACWY-CRM) vaccine |
| NCT02193152 Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer | P2 | Terminated | 16 | Open-label | Pazopanib |
| NCT00159484 Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | Colon Cancer, Colorectal Cancer | P1P2 | Unknown | 75 | Open-label | EPO906, celecoxib |
| NCT00311012 SPP100 Dose Finding Study in Japan | Hypertension | P2 | Completed | 445 | RCT, Double-blind | Aliskiren |
| NCT00767819 Treatment of Patients With RAD001 With Progressive Sarcoma | Progressive Sarcoma | P2 | Completed | 71 | Open-label | Everolimus |
| NCT00645788 Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis | Cystic Fibrosis | P2 | Completed | 288 | RCT, Double-blind | Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo, Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo |
| NCT00527475 Ranibizumab and Reduced Fluence PDT for AMD | Macular Degeneration | P2 | Completed | 60 | RCT, Single-blind | ranibizumab, verteporfin |
| NCT02072057 Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases. | Cancer Cachexia | P2 | Terminated | 8 | Open-label | Ruxolitinib |
| NCT00379483 Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload | Transfusional Iron Overload | P2 | Completed | 66 | Open-label | Deferasirox |
| NCT04382053 Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia | COVID-19 Pneumonia, Impaired Respiratory Function | P2 | Completed | 143 | RCT, Open-label | DFV890, Standard of Care (SoC) |
| NCT01266070 TKI 258 in Von Hippel-Lindau Syndrome (VHL) | Von Hippel-Lindau Syndrome | P2 | Terminated | 6 | Open-label | Dovitinib |
| NCT01934894 Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | Metastatic Breast Cancer With Intracranial Metastases | P2 | Terminated | 11 | Open-label | cabazitaxel, lapatinib |
| NCT01543854 Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure | Acute Heart Failure | P2 | Completed | 71 | RCT, Double-blind | RLX030, Placebo |
| NCT02991807 RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome | PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | P1P2 | Completed | 46 | RCT, Double-blind | RAD001, Placebo |
| NCT01528345 Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | Metastatic Breast Cancer | P2 | Terminated | 97 | RCT, Double-blind | Dovitinib, Fulvestrant, Dovitinib Placebo |
| NCT00411619 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma | P1P2 | Completed | 28 | Open-label | Everolimus |
| NCT01491932 Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | Dyskinesias, Parkinson Disease | P2 | Completed | 129 | Open-label | AFQ056 |
| NCT00237198 Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment | Postmenopausal Women With Advanced Breast Cancer | P2 | Completed | 47 | Open-label | Letrozole |
| NCT00101101 Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | Lymphoma | P2 | Completed | 43 | Open-label | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2 |
| NCT01619332 Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 | Type II Diabetes | P1P2 | Completed | 220 | Double-blind | Placebo, Sitagliptin, LEZ763 |
| NCT02534909 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | P2 | Completed | 10 | Open-label | LFG316, LNP023 |
| NCT00813592 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma | Cancer | P2 | Terminated | 2 | Open-label | SOM230B |
| NCT01787552 A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | Primary Myelofibrosis, Thrombocytosis | P1P2 | Completed | 50 | Open-label | LDE225, INC424 |
| NCT00518726 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects | Influenza | P2 | Completed | 125 | Open-label | Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008 |
| NCT00171808 Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer | Endometrial Cancer | P2 | Completed | 26 | Open-label | Letrozole |
| NCT00464776 Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy | Diabetes Mellitus, Type 2 | P1P2 | Completed | 26 | RCT, Double-blind | Aliskiren, Aliskiren, Aliskiren, Aliskiren |
| NCT01390350 Ilaris® Effects in Schnitzler Syndrome (ILESCH) | Schnitzler Syndrome | P2 | Completed | 20 | RCT, Double-blind | Canakinumab, Placebo |
| NCT00348790 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma | Brain and Central Nervous System Tumors, Sarcoma | P2 | Completed | 25 | Open-label | vatalanib |
| NCT01806610 Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease | Chronic-kidney Disease Stage 5D on Stable Hemodialysis | P2 | Withdrawn | — | RCT, Double-blind | BPS804, Placebo |
| NCT02619617 Safety and Efficacy Study of SOM230 s.c. in Cluster Headache | Cluster Headache - Episodic and Chronic | P2 | Terminated | 28 | Double-blind | SOM230, Placebo |
| NCT01423110 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis | Sporadic Inclusion Body Myositis | P2 | Completed | 14 | RCT, Double-blind | BYM338, Placebo |
| NCT02291913 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | Breast Cancer | P2 | Completed | 48 | Open-label | Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine |
| NCT01860989 A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection | Cure Rate | P2 | Completed | 11 | Open-label | KAE609, KAE609, KAE609, KAE609 |
| NCT00165347 Protein Tyrosine Kinases (PTK) in Multiple Myeloma | Multiple Myeloma | P2 | Completed | 10 | Open-label | PTK787/ZK222584 |
| NCT00193349 Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer | Lung Cancer | P2 | Completed | 60 | Open-label | Imatinib, Irinotecan, Carboplatin |
| NCT00333138 Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | P2 | Completed | 281 | RCT, Double-blind | FTY720, Placebo |
| NCT01836458 A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection | Malaria | P2 | Completed | 25 | Open-label | KAE609 |
| NCT03100058 A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults | Obesity, Overweight | P2 | Completed | 460 | RCT, Double-blind | LIK066, Placebo |
| NCT02706691 BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | FGFR Gene Amplification, FGFR1 Gene Amplification | P2 | Terminated | 1 | Open-label | BGJ398 |
| NCT00557440 Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma | Asthma | P2 | Completed | 37 | RCT, Double-blind | fluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate, placebo to indacaterol/mometasone, placebo to fluticasone propionate/salmeterol |
| NCT04868968 Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) | Familial Cold Autoinflammatory Syndrome | P2 | Completed | 4 | Open-label | DFV890 |
| NCT00770965 Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis | Chronic Plaque Psoriasis | P2 | Completed | 80 | RCT, Double-blind | AIN457, Placebo |
| NCT00265200 Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer | Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung | P2 | Terminated | 28 | Open-label | zoledronic acid |
| NCT01613677 Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer | Treatment for Metastatic or Locally Advanced Cervical Cancer | P2 | Withdrawn | — | RCT, Open-label | BKM120 |
| NCT02236572 Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | Breast Cancer | P2 | Terminated | 17 | Open-label | Everolimus |
| NCT01238692 A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | Diffuse Large B Cell Lymphoma | P2 | Completed | 42 | RCT, Open-label | LBH589, Rituximab |
| NCT00811590 Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome | Peutz-Jeghers Syndrome | P2 | Terminated | 3 | Open-label | Everolimus |
| NCT00499603 Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | Breast Cancer | P2 | Unknown | 62 | RCT, Open-label | Paclitaxel, 5-Fluorouracil, Epirubicin, Cyclophosphamide, RAD001 |
| NCT01294579 Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | Lymphoma, Non-Hodgkin | P2 | Completed | 49 | Open-label | Ofatumumab, Bendamustine |
| NCT00644878 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib | Chronic Myelogenous Leukemia - Chronic Phase | P2 | Terminated | 18 | Open-label | Nilotinib |
| NCT00511303 Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | Chronic Myeloid Leukemia | P2 | Completed | 200 | Open-label | STI571 |
| NCT01166139 Nilotinib in the Treatment of Systemic Sclerosis | Systemic Sclerosis | P2 | Completed | 10 | Open-label | Nilotinib (Tasigna) |
| NCT03297294 Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN) | Painful Diabetic Neuropathy | P2 | Terminated | 142 | RCT, Double-blind | EMA401, Placebo |
| NCT01431794 Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P1P2 | Terminated | 23 | RCT, Open-label | LDE225-600mg, Gemcitabine, nab-paclitaxel, LDE225-400mg, LDE225-800mg |
| NCT04529044 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | P2 | Not Yet Recruiting | 10 | Open-label | Lutetium Lu 177 Dotatate |
| NCT03025698 A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia | Aplastic Anemia | P2 | Completed | 51 | Open-label | Eltrombopag, hATG, CsA |
| NCT00846989 Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension | Glaucoma, Ocular Hypertension | P1P2 | Completed | 276 | RCT, Single-blind | RKI983A, RKI983A, Latanoprost |
| NCT01004510 Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer | Malignant Pleural Effusion, Non Small Cell Lung Cancer | P2 | Terminated | 3 | Open-label | zoledronic acid |
| NCT01376310 GSK1120212 Rollover Study | Cancer | P2 | Terminated | 159 | Open-label | GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212, Pemetrexed + GSK1120212, Carboplatin + GSK1120212, Nab-paclitaxel + GSK1120212, Gemcitabine + GSK1120212, Everolimus + GSK1120212 |
| NCT00108836 Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder | Anxiety Disorders | P2 | Completed | 400 | RCT, Double-blind | XBD173 |
| NCT04836858 A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis. | Atopic Dermatitis | P2 | Completed | 71 | RCT, Double-blind | CMK389, Placebo |
| NCT01124864 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. | Non-small-cell Lung Cancer | P2 | Completed | 153 | Open-label | AUY922 |
| NCT00154349 Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | P2 | Completed | 8 | Open-label | Imatinib Mesylate |
| NCT05111249 A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease | Early Manifest Huntington Disease | P2 | Terminated | 26 | RCT, Double-blind | Branaplam, Placebo |
| NCT04323436 Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | Carcinoma, Non-Small-Cell Lung | P2 | Terminated | 31 | RCT, Double-blind | Spartalizumab, Capmatinib, spartalizumab placebo |
| NCT04878432 STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | Myelodysplastic Syndrome (MDS) | P2 | Terminated | 39 | Open-label | MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine) |
| NCT01788176 The Use of Zoledronic Acid to Complex Regional Pain Syndrome | Complex Regional Pain Syndromes | P2 | Unknown | 40 | RCT, Double-blind | Zoledronic acid, Placebo |
| NCT01068860 To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | P2 | Completed | 246 | RCT, Double-blind | Canakinumab 150 mg, Placebo to Canakinumab |
| NCT00193180 Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 37 | Open-label | Imatinib, Docetaxel |
| NCT00814385 Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 | Influenza | P1P2 | Completed | 606 | RCT, Double-blind | Aflunov (Single prime, single boost), Aflunov (Single prime, single boost), Aflunov (single prime, single boost), Aflunov (single prime, single boost), Aflunov (Double prime, single boost), Aflunov (double prime, single boost), Aflunov (double prime, single boost), Aflunov (double prime, single boost), Aflunov (No prime, single boost) |
| NCT02000882 STAR Cape+BKM120 MBC With Brain Met | Brain Metastases, Breast Cancer | P2 | Completed | 10 | Open-label | BKM120, capecitabine, Trastuzumab |
| NCT01708174 A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | Medulloblastoma | P2 | Completed | 22 | Open-label | LDE225, TMZ |
| NCT00124280 Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Non-small-cell Lung Carcinoma | P2 | Completed | 85 | Open-label | RAD001 |
| NCT00887861 Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery | Seizures, Epilepsy | P2 | Completed | 37 | RCT, Double-blind | Investigational new drug, company code: BGG492, Placebo |
| NCT01088880 Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever | Familial Mediterranean Fever | P2 | Completed | 10 | Open-label | Canakinumab |
| NCT01252251 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | Uveal Melanoma | P2 | Completed | 14 | Open-label | RAD001 (Everolimus) and Pasireotide (SOM230) LAR |
| NCT00323362 Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer | Lung Cancer | P2 | Terminated | 17 | Open-label | gemcitabine hydrochloride, imatinib mesylate |
| NCT00732771 Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism | Primary Hyperaldosteronism | P2 | Completed | 12 | Single-blind | LCI699 |
| NCT01791192 Study of FTY720 in Patients With Uveitis | Acute Noninfectious Posterior, Intermediate, or Pan Uveitis | P2 | Withdrawn | — | RCT, Single-blind | FTY720, Oral Corticosteroid |
| NCT00242333 A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD | COPD | P2 | Completed | 300 | RCT, Double-blind | AD 237 |
| NCT00582790 Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | Kidney Cancer | P2 | Terminated | 12 | Open-label | IL2, Zoledronic acid |
| NCT01730768 A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients | Schizophrenia | P2 | Completed | 147 | RCT, Double-blind | AQW051, Placebo |
| NCT01336634 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | Cancer | P2 | Completed | 177 | Open-label | Dabrafenib, Trametinib |
| NCT00956449 Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects | Influenza, Seasonal Influenza | P2 | Completed | 126 | Open-label | Seasonal Influenza Vaccine |
| NCT01636076 Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) | COPD | P2 | Completed | 629 | RCT, Double-blind | QMF149, Salmeterol |
| NCT01364389 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica | Polymyalgia Rheumatica, Inflammatory Diseases | P2 | Terminated | 16 | RCT, Double-blind | AIN457, ACZ885, Prednisone, Placebo |
| NCT01289912 Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) | Tuberous Sclerosis Complex | P2 | Completed | 52 | RCT, Double-blind | RAD001, Placebo |
| NCT06031844 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP | Coronary Heart Disease | P2 | Completed | 24 | RCT, Double-blind | DFV890, DFV890 Placebo |
| NCT01566747 Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | Renal Cell Carcinoma | P2 | Completed | 43 | Open-label | Pazopanib |
| NCT00736047 Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking. | Smokers | P2 | Completed | 200 | RCT, Double-blind | NIC002, Placebo |
| NCT02353728 Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy | Chronic Myeloid Leukemia | P2 | Completed | 16 | Open-label | Nilotinib |
| NCT02513667 Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | ALK-positive Non-small Cell Lung Cancer | P2 | Terminated | 14 | Open-label | Ceritinib |
| NCT06997159 A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR). | Localized Cutaneous Leishmaniasis | P2 | Not Yet Recruiting | 250 | RCT, Double-blind | LXE408, Miltefosine 50 MG Oral Capsule [Impavido], Placebo to LXE408 |
| NCT00421590 Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide). | Health Postmenopausal Women | P2 | Completed | 38 | RCT, Double-blind | SMC021 |
| NCT00930982 Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis | Bronchiectasis | P2 | Completed | 124 | RCT, Double-blind | Ciprofloxacin (Cipro, BAYQ3939), Placebo |
| NCT04410523 Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma | Asthma | P2 | Terminated | 335 | RCT, Double-blind | CSJ117, Placebo |
| NCT00451035 Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase | Chronic Myeloid Leukemia in Chronic Phase | P2 | Terminated | 29 | Open-label | LBH589 |
| NCT00142974 Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy | Diabetic Gastropathy | P2 | Terminated | 120 | RCT, Double-blind | Tegaserod |
| NCT02977689 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | Glioma | P2 | Withdrawn | — | Open-label | IDH305 |
| NCT00422344 A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma, Kidney Cancer | P1 | Completed | 20 | Open-label | RAD001, Sunitinib |
| NCT00395395 Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women | Postmenopausal Osteoporosis | P1 | Completed | 56 | RCT, Double-blind | Oral salmon calcitonin, salmon calcitonin nasal spray |
| NCT01857193 Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | Breast Cancer | P1 | Completed | 132 | Open-label | ribociclib (LEE011), Exemestane, Everolimus (RAD001) |
| NCT00550199 LBH589 and Gemcitabine in the Treatment of Solid Tumors | Solid Tumors | P1 | Terminated | 17 | Open-label | LBH589, Gemcitabine |
| NCT02088684 Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | Breast Cancer | P1 | Completed | 70 | Open-label | LEE011, BYL719, fulvestrant, BKM120 |
| NCT02947152 HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Epithelial Ovarian Cancer, Renal Cell Carcinoma | P1 | Terminated | 9 | Open-label | HKT288 |
| NCT00961038 Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Pulmonary Disease, Chronic Obstructive | P1 | Completed | 19 | RCT, Single-blind | Ciprofloxacin (PulmoSphere, BAYQ3939), Ciprofloxacin (PulmoSphere, BAYQ3939), Placebo |
| NCT06130540 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | Giant Cell Arteritis, Polymyalgia Rheumatica | P1 | Completed | 65 | RCT, Open-label | Secukinumab |
| NCT01065467 Panobinostat (LBH589) in Patients With Metastatic Melanoma | Melanoma, Malignant Melanoma | P1 | Completed | 16 | Open-label | LBH589 |
| NCT00424541 Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension | Hypertension | P1 | Completed | 34 | RCT, Double-blind | SPP100 (aliskiren) |
| NCT05330286 Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter. | Healthy Volunteers | P1 | Terminated | 9 | RCT, Double-blind | LMI070, LMI070, LMI070, LMI070 |
| NCT02089087 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | P1 | Completed | 75 | RCT, Double-blind | CFZ533, Placebo |
| NCT00328458 EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients | Central Nervous System Neoplasms, Head and Neck Neoplasms | P1 | Completed | 39 | RCT, Open-label | EPO906 (epothilone B) |
| NCT00984113 Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | Renal Impairment | P1 | Terminated | 44 | Open-label | Elinogrel |
| NCT01442259 An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects | Mild Moderate, or Severe Renal Impairment | P1 | Completed | 48 | Open-label | AFQ056 |
| NCT03696771 Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | NON-breast HER2+ Malignancies | P1 | Completed | 18 | Open-label | NJH395 |
| NCT00419887 Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers | Healthy | P1 | Completed | 60 | RCT, Double-blind | Vildagliptin (LAF237) |
| NCT00828594 Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1 | Terminated | 130 | Open-label | RAD001, RAD001, sorafenib |
| NCT01697605 A Phase I Study of Oral BGJ398 in Asian Patients | Tumor With Alterations of the FGF-R | P1 | Completed | 9 | Open-label | BGJ398 |
| NCT01242774 Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML) | P1 | Completed | 46 | Open-label | Panobinostat |
| NCT00879905 A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors | Advanced Solid Malignancies | P1 | Completed | 64 | Open-label | HSP990 |
| NCT01217177 A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer | Locally Advanced Cervical Cancer | P1 | Completed | 14 | Open-label | everolimus |
| NCT02048787 Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. | Renal Impairment | P1 | Completed | 19 | Open-label | Buparlisib |
| NCT02240719 Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | P1 | Completed | 20 | Open-label | everolimus, bendamustine hydrochloride |
| NCT00183833 Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors | Colon Cancer, Colorectal Cancer | P1 | Completed | 40 | Open-label | capecitabine, imatinib mesylate |
| NCT00486317 Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis | Osteoarthritis | P1 | Completed | — | RCT, Double-blind | Oral salmon calcitonin, salmon calcitonin nasal spray |
| NCT00419536 Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone | Hormone Refractory Prostate Cancer Disease | P1 | Terminated | 108 | Open-label | LBH589 |
| NCT00410501 Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects | Healthy | P1 | Completed | 20 | Open-label | Indacaterol (QAB149) |
| NCT00417196 Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers. | Healthy | P1 | Completed | 32 | RCT, Double-blind | QAX576 |
| NCT00620594 A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | Breast Cancer, Advanced Solid Tumors | P1 | Completed | 183 | Open-label | BEZ235 |
| NCT00613132 Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | Glioblastoma, Gliosarcoma | P1 | Completed | 78 | Open-label | Gleevec, RAD001, and Hydroxyurea |
| NCT01646684 Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | Castration Resistant Prostate Cancer | P1 | Completed | 9 | Open-label | SOM230 |
| NCT00586443 BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) | Solid Tumors | P1 | Completed | 56 | Open-label | bevacizumab, everolimus, panitumumab |
| NCT02607774 Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis | Moderate to Severe Plaque Psoriasis | P1 | Completed | 25 | Open-label | Midazolam, AIN457 |
| NCT00418509 Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers | Healthy | P1 | Completed | 24 | RCT, Open-label | Mometasone furoate, Formoterol fumarate |
| NCT01428297 A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome | Healthy Volunteers, Atopic Dermatitis | P1 | Completed | 12 | RCT, Double-blind | BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, Placebo (Vehicle), BPR277, Placebo (Vehicle) |
| NCT01576666 Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Dose Escalation, Safety | P1 | Completed | 120 | Open-label | LDE225, BKM120 |
| NCT02878616 Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316 | Kidney Transplantation | P1 | Completed | 8 | RCT, Open-label | LFG316, IVIG |
| NCT00446004 Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers | Healthy | P1 | Completed | 15 | RCT, Open-label | Imatinib Mesylate, Omeprazole |
| NCT01490749 Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | Esophageal Cancer, Neoplasms, Esophageal | P1 | Completed | 17 | Open-label | RAD001, XELOX, Carboplatin |
| NCT02403193 Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer (NSCLC) | P1 | Completed | 92 | Open-label | PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg, PBF-509_640 mg, Combo PBF-509 (160 mg) + PDR001, Combo PBF-509 (320 mg) + PDR001, Combo PBF-509 (640 mg) + PDR001, RP2D (PBF-509+PDR001)_immuno naïve, Experimental: RP2D (PBF-509+PDR001)_immuno treated |
| NCT05036668 Study of Efficacy and Safety of ABO809 in Healthy Participants | Cryptosporidium Infection, Cryptosporidiosis | P1 | Completed | 30 | Open-label | Cryptosporidium parvum oocysts (ABO809) |
| NCT01007968 Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function | Advanced Solid Tumors | P1 | Completed | 25 | Open-label | LBH589 |
| NCT02720926 Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | Colorectal Cancer, Gastric Cancer | P1 | Terminated | 3 | Open-label | Xeloda,, Oxaliplatin, TKI258 |
| NCT01428492 Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | Multiple Myeloma | P1 | Completed | 90 | Open-label | GSK2110183, Bortezomib, Dexamethasone |
| NCT00487058 A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 28 | Open-label | Gimatecan |
| NCT01456676 Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | P1 | Completed | 11 | Open-label | Nilotinib + LDE225 |
| NCT00264420 Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation | Bone Metastases, Breast Cancer | P1 | Completed | 4 | Open-label | zoledronic acid |
| NCT02414724 Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma | Lymphoma, Solid Neoplasm | P1 | Terminated | 10 | Open-label | Gemcitabine Hydrochloride, Ribociclib |
| NCT00150891 Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection | Renal Failure, Chronic | Completed | 84 | — | cyclosporine A, tacrolimus, azathioprine, mycophenolate mofetil | |
| NCT03834922 Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment | Pain, Postoperative | Completed | 3,322 | — | — | |
| NCT05575843 Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS® | Multiple Sclerosis (MS) | N/A | Completed | 101 | RCT, Single-blind | — |
| NCT01360385 Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab | Central Retinal Vein Occlusion | Completed | 24 | — | — | |
| NCT05146830 A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04 | Cystinosis | By Invite | 50 | — | — | |
| NCT00149981 A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation | Organ Transplantation | NO_LONGER_AVAILABLE | — | — | everolimus (RAD) | |
| NCT07309887 This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer. | Early Breast Cancer | Not Yet Recruiting | 100,000 | — | — | |
| NCT04781881 Special Drug Use Surveillance for Entresto Tablets | Chronic Heart Failure | Completed | 688 | — | Entresto | |
| NCT04025502 Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects | Schizophrenia | Completed | 161 | — | — | |
| NCT01705132 Urinary Biomarkers of the Progression of Alport Kidney Disease | Alport Syndrome | Completed | 80 | — | — | |
| NCT00226200 Soluble CD23 Expression in Asthma Patients Treated With OMA | Asthma | N/A | Terminated | 80 | RCT, Double-blind | Omalizumab |
| NCT00338247 EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | Neoplasms, Breast | APPROVED_FOR_MARKETING | — | — | lapatinib + capecitabine | |
| NCT01562847 Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib | Chronic Myeloid Leukemia | Unknown | 125 | — | Nilotinib | |
| NCT06148493 Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | Chronic Myeloid Leukemia | Completed | 425 | — | — | |
| NCT05368818 An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source | Plaque Psoriasis | Completed | 767 | — | — | |
| NCT07378943 A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies | Muscular Atrophy, Spinal | Completed | 4,114 | — | — | |
| NCT00627991 Blood Pressure Lowering in Acute Stroke Trial (BLAST) | Cerebrovascular Accident | N/A | Withdrawn | — | RCT, Double-blind | Valsartan |
| NCT05834075 A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India | Neurovascular Age-related Macular Degeneration | Completed | 63 | — | — | |
| NCT02264665 OPALINE : A Study Of Morbidity And Mortality At 2 Years | Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive | Completed | 144 | — | sunitinib, everolimus, chemotherapies recommended in france | |
| NCT01213641 Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients | Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS) | Completed | 288 | — | — | |
| NCT01230502 Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation | Liver Transplant | N/A | Terminated | 11 | RCT, Open-label | Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy |
| NCT07214857 Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States | Cardiovascular Disease | Completed | 1,385 | — | — | |
| NCT01025063 Use of Spectral OCT in Combination Therapy | Choroidal Neovascularization | Completed | 15 | — | — | |
| NCT02123199 Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD | Chronic Obstructive Pulmonary Disease | Completed | 103 | — | Indacaterol (Onbrez®) /QAB149 | |
| NCT02786186 A Registry of Patients With Moderate to Severe Plaque Psoriasis | Psoriasis | Completed | 2,376 | — | Secikinumab | |
| NCT05611229 Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | Metastatic Melanoma | Completed | 1,975 | — | Nivolumab, Pembrolizumab | |
| NCT02833493 Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload | Aplastic Anemia, Dysmyelopoietic Syndromes | Unknown | 80 | — | — | |
| NCT04360005 Managed Access Programs for ABL001, Asciminib | Chronic Myeloid Leukemia in Chronic Phase | AVAILABLE | — | — | Asciminib | |
| NCT06248658 Assessment of the Impact of Clinical Decision Support Systems Included in Electronic Health Records | Chronic Heart Failure (CHF) | Unknown | 1,000 | — | — | |
| NCT05424523 Effectiveness and Safety of Omalizumab in Children With Allergic Asthma. | Allergic Asthma | Completed | 200 | — | Omalizumab | |
| NCT00512213 Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery | Major Abdominal Surgery | N/A | Completed | 154 | RCT, Double-blind | — |
| NCT00098189 Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis | Psoriasis | Completed | — | — | — | |
| NCT00749372 MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions | Myelodysplastic Syndrome (MDS) | N/A | Completed | 15 | Open-label | — |
| NCT06178770 Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up | Neovascular Age-related Macular Degeneration | Completed | 414 | — | — | |
| NCT02871375 Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal | Refractive Error | N/A | Completed | 170 | RCT, Single-blind | — |
| NCT06580886 Validation of Handheld Ultrasound Devices in Rheumatology | Psoriatic Arthritis | Completed | 30 | — | — | |
| NCT00747994 Genetic Study of Families Affected by Paget's Disease of Bone | Paget's Disease of Bone | Completed | 83 | — | — | |
| NCT05170724 Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | AVAILABLE | — | — | Remibrutinib | |
| NCT04847596 A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab | Relapsing Multiple Sclerosis | Completed | 25 | — | — | |
| NCT03413722 Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus | End Stage Renal Disease | Completed | 30 | — | Tacrolimus, Everolimus | |
| NCT01398631 A Comparison of the TIMI, GRACE and HEART Scores | Acute Coronary Syndrome | Completed | 2,440 | — | — | |
| NCT01165983 The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes | Diabetes Type 2 | N/A | Completed | 124 | RCT, Double-blind | Placebo, Aliskiren |
| NCT05349201 CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL) | Completed | 273 | — | — | |
| NCT04890236 Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early P1 | Completed | 4 | Open-label | Duvelisib, Tisagenlecleucel |
| NCT05038631 Managed Access Programs for LEE011, Ribociclib | Breast Cancer | AVAILABLE | — | — | Ribociclib | |
| NCT03746197 Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | N/A | Unknown | 60 | RCT, Double-blind | — |
| NCT05157087 XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States | Asthma | Completed | 16,246 | — | Omalizumab | |
| NCT07188428 Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment | Leukemia, Chronic Myeloid | Completed | 2,298 | — | — | |
| NCT05576792 A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China | Retinopathy of Prematurity | Completed | 62 | — | — | |
| NCT00580281 Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors | Gastric Cancer, Leukemia | N/A | Completed | 33 | Open-label | — |
| NCT05714371 Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | Melanoma | Completed | 618 | — | Nivolumab, Ipilimumab + nivolumab, Pembrolizumab, Dabrafenib + trametinib | |
| NCT01933646 Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China | Invasive Group B Streptococcal Disease | Completed | 10 | — | — | |
| NCT05407740 "Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease | Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate, Progression of Kidney Failure and or All-cause Mortality | Completed | 355 | — | — | |
| NCT05121662 COVID-19 Vaccine Biomarker Study in Multiple Sclerosis | Multiple Sclerosis, COVID-19 | Completed | 154 | — | — | |
| NCT02204553 Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | NO_LONGER_AVAILABLE | — | — | Panobinostat | |
| NCT05476562 Study Conducted Among Patients With CML | Chronic Myeloid Leukemia | Completed | 3,234 | — | — | |
| NCT04476706 Canakinumab MAP in COVID-19 Pneumonia With CRS | Cytokine Release Syndrome in COVID-19-induced Pneumonia | NO_LONGER_AVAILABLE | — | — | canakinumab | |
| NCT04935411 Russian Registry of Patients With nAMD | Neovascular Age-Related Macular Degeneration | Terminated | 2,665 | — | — | |
| NCT07222423 A Study of the Epidemiology and Hospital Management of Patients With PROS in France | PIK3CA-Related Overgrowth Spectrum | Completed | 3,605 | — | — | |
| NCT06760624 Effectiveness of Ofatumumab in Real-world Practice | Multiple Sclerosis | Completed | 779 | — | — | |
| NCT06460324 A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab | Multiple Sclerosis | Completed | 38 | — | — | |
| NCT05215561 Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP | Psoriasis Vulgaris, Psoriatic Arthritis | Completed | 36 | — | — | |
| NCT04792580 The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease | Graft-versus-host-disease, Ocular Graft-versus-host Disease | Early P1 | Completed | 30 | RCT, Double-blind | Lifitegrast 5% Ophthalmic Solution, Placebo |
| NCT02662868 Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments | Metastatic Breast Cancer | Completed | 767 | — | — | |
| NCT06459232 Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies | Multiple Sclerosis | Completed | 143 | — | — | |
| NCT05613140 Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure | Chronic Heart Failure | Completed | 9,230 | — | sacubitril/valsartan | |
| NCT05162638 Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation | Multiple Sclerosis, Healthy | N/A | By Invite | 24 | Open-label | — |
| NCT01911871 Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations | Thalassemia, Sickle Cell Disease | Completed | 110 | — | Blood sample | |
| NCT05611216 Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation | Chronic Myeloid Leukemia | Completed | 164 | — | — | |
| NCT05304949 Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity | Retinopathy of Prematurity | Completed | 69 | — | — | |
| NCT00936585 NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease | Colitis, Crohn's Disease | N/A | Terminated | 2 | Open-label | — |
| NCT03894020 GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) | Dry Age-related Macular Degeneration, Macular Degeneration | Terminated | 83 | — | — |